BridgeBio Pharma, Inc. (BBIO) Stock Overview
Explore BridgeBio Pharma, Inc.’s financial performance, market position, analyst ratings, and future outlook.
BridgeBio Pharma, Inc. (BBIO)
Key Financials
Key Financials
Market Cap
16.2B
P/E Ratio
-22.46
EPS (TTM)
$-3.74
ROE
0.36%
BBIO Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of BridgeBio Pharma, Inc. (BBIO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 64.03, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $82.59.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -22.46 and a market capitalization of 16.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.